Trial Profile
PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2014
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 02 Jul 2014 New trial record